We define a strategy to selectively target colon cancer cells by exploiting their propensity for increased glycolytic flux, using a non-metabolizable glucose analog to enhance sensitivity to TRAIL-induced apoptosis through enhanced DR5 expression combined with downstream modulation of MAPK signaling and subsequent miRNA expression modulation. Here, TNFRSF10B is linked to colonic neoplasm.